文 献 7）Hosohata K, Masuda S, Katsura T, Takada Y, Kaido T, Ogura Y, et al. Impact of intestinal CYP2C19 genotypes on the interaction between tacrolimus and omeprazole, but not lansoprazole, in adult living-donor liver transplant patients. Drug Metab Dispos 2009; 37: 821–6. 8）Wang DD, Chen X, Fu M, Zheng QS, Xu H, Li ZP. Model extrapolation to a real-world dataset: evaluation of tacrolimus population pharmacokinetics and drug interaction in pediatric liver transplantation patients. Xenobiotica 2020; 50: 371–9. 9）Schumacher L, Leino AD, Park JM. Tacrolimus i n t r a p a t i e n t v a r i a b i l i t y i n s o l i d o r g a n transplantation: A multiorgan perspective. Pharmacotherapy 2021; 41: 103–18.10）Calvo PL, Serpe L, Brunati A, Nonnato A, Bongioanni D, Olio DD, et al. Donor CYP3A5 genotype influences tacrolimus disposition on the first day after pediatric liver transplantation. Br J Clin Pharmacol 2017; 83: 1252–62.11）Goldschmidt I, Chichelnitskiy E, Rübsamen N, Jaeger VK, Karch A, D'Antiga L, et al. Diagnosing acute cellular rejection after paediatric liver transplantation: is there room for interleukin profiles?. Children 2023; 14: 985711.小児肝移植後タクロリムス治療のPK/PD/PGxおよび免疫応答に基づく急性拒絶反応発症因子の検討 1）日本 TDM 学会、日本移植学会（編） 免疫抑制薬TDM標準化ガイドライン［臓器移植編］．金原出版株式会社、2018． 2）Kearns GL, Abdel-Rahman SM, Alander SW, B l o w e y D L , L e e d e r J S , K a u f f m a n R E . Developmental pharmacology–drug disposition, action, and therapy in infants and children. N Engl J Med 2003; 349: 1157–67. 3）Meziyerh S, van Gelder T, Kers J, van der Helm D, van der Boog PJM, de Fijter JW, et al. Tacrolimus and mycophenolic acid exposure are associated with biopsy-proven acute rejection: a study to provide evidence for longer-term target ranges. Clin Pharma and Ther 2023; 114: 192–200． 4）Maguire M, Franz T, Hains DS. A clinically significant interaction between tacrolimus and multiple proton pump inhibitors in a kidney transplant recipient. Pediatr Transplant 2012; 16: 217–20. 5）Chauhan SK, Saban DR, Lee HK, Dana R. Levels of Foxp3 in regulatory T cells reect their functional status in transplantation. J Immunol 2009; 182: 148-53. 6）Millán O, Rafael-Valdivia L, Torrademé E, López A, Fortuna V, Sánchez-Cabus S, et al. Intracellular IFN-c and IL-2 expression monitoring as surrogate markers of the risk of acute rejection and personal drug response in de novo liver transplant recipients. Cytokine 2013; 61: 556–64.269
元のページ ../index.html#287